{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:45:47Z","timestamp":1789400747757,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose-expansion results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients received nanoparticle-formulated AZD2811 500\u2009mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8). Dose-expansion endpoints included: preliminary antitumour activity, safety\/tolerability, pharmacokinetics, and biomarker-based disease monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One of 21 enrolled patients achieved a partial response for an objective response rate of 4.8%; stable disease \u22656 weeks was observed in 10 patients (47.6%). The most common AZD2811-related AEs were decreased neutrophil and white blood cell count, anaemia, and decreased platelet count; grade \u22653 AZD2811-related AEs occurred in 15\/21 patients. Baseline ctDNA levels were prognostic, and on-treatment ctDNA changes mirrored clinical response and identified progression early, suggesting it could be an effective surrogate for tumour tissue. Molecular profiling of paired tumour biopsies demonstrated AZD2811 pharmacodynamic activity and identified genes\/pathways potentially linked to response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A personalised surveillance strategy may provide a novel avenue to monitor SCLC, supporting further investigation and potential broader clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>NCT02579226<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03414-0","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:51:07Z","timestamp":1775188267000},"page":"1592-1604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed\/refractory small-cell lung cancer"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa L.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Ciardullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-0718","authenticated-orcid":false,"given":"Carl M.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Cardnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-8309","authenticated-orcid":false,"given":"Luis","family":"Tobalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-4655","authenticated-orcid":false,"given":"Sophie E.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rodriguez-Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myria","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma V.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Schalkwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Sainsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Overend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Elizabeth","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Szekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cosaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Howard","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-2677","authenticated-orcid":false,"given":"Lauren A.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"3414_CR1","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog BH, Devarakonda S, Govindan R. Overcoming Chemotherapy Resistance in SCLC. J Thorac Oncol. 2021;16:2002\u201315.","journal-title":"J Thorac Oncol"},{"key":"3414_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346\u201360.e7.","journal-title":"Cancer Cell"},{"key":"3414_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823\u201335.","journal-title":"J Thorac Oncol"},{"key":"3414_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3414_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104\u201310.","journal-title":"Nat Genet"},{"key":"3414_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47\u201353.","journal-title":"Nature"},{"key":"3414_CR7","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","volume":"13","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Colon CI, et al. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation. Cancer Discov. 2023;13:1572\u201391.","journal-title":"Cancer Discov"},{"key":"3414_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.gde.2003.11.006","volume":"14","author":"P Meraldi","year":"2004","unstructured":"Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004;14:29\u201336.","journal-title":"Curr Opin Genet Dev"},{"key":"3414_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","volume":"5","author":"J Fu","year":"2007","unstructured":"Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5:1\u201310.","journal-title":"Mol Cancer Res"},{"key":"3414_CR10","doi-asserted-by":"publisher","first-page":"23937","DOI":"10.18632\/oncotarget.14893","volume":"8","author":"A Tang","year":"2017","unstructured":"Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8:23937\u201354.","journal-title":"Oncotarget"},{"key":"3414_CR11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-07-2179","volume":"14","author":"O Gautschi","year":"2008","unstructured":"Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008;14:1639\u201348.","journal-title":"Clin Cancer Res"},{"key":"3414_CR12","first-page":"5168","volume":"62","author":"T Ota","year":"2002","unstructured":"Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1\/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002;62:5168\u201377.","journal-title":"Cancer Res"},{"key":"3414_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.lungcan.2012.12.018","volume":"80","author":"M Takeshita","year":"2013","unstructured":"Takeshita M, Koga T, Takayama K, Ijichi K, Yano T, Maehara Y, et al. Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer. 2013;80:85\u201390.","journal-title":"Lung Cancer"},{"key":"3414_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2159-8290.CD-18-0389","volume":"9","author":"MG Oser","year":"2019","unstructured":"Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on Aurora B kinase for survival. Cancer Discov. 2019;9:230\u201347.","journal-title":"Cancer Discov"},{"key":"3414_CR15","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/cncr.28113","volume":"119","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Martinelli G, Jabbour EJ, Quintas-Cardama A, Ando K, Bay JO, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013;119:2611\u20139.","journal-title":"Cancer"},{"key":"3414_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10637-012-9825-7","volume":"31","author":"GK Schwartz","year":"2013","unstructured":"Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest N Drugs. 2013;31:370\u201380.","journal-title":"Invest N Drugs"},{"key":"3414_CR17","doi-asserted-by":"publisher","first-page":"325ra17","DOI":"10.1126\/scitranslmed.aad2355","volume":"8","author":"S Ashton","year":"2016","unstructured":"Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016;8:325ra17.","journal-title":"Sci Transl Med"},{"key":"3414_CR18","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/cncr.33048","volume":"126","author":"S Park","year":"2020","unstructured":"Park S, Shim J, Mortimer PGS, Smith SA, Godin RE, Hollingsworth SJ, et al. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer. 2020;126:4002\u201312.","journal-title":"Cancer"},{"key":"3414_CR19","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/s41416-023-02185-2","volume":"128","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Wang JS, Falchook G, Greenlees C, Jones S, Strickland D, et al. Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours. Br J Cancer. 2023;128:1906\u201315.","journal-title":"Br J Cancer"},{"key":"3414_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jtho.2017.09.1951","volume":"13","author":"K Almodovar","year":"2018","unstructured":"Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, et al. Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. J Thorac Oncol. 2018;13:112\u201323.","journal-title":"J Thorac Oncol"},{"key":"3414_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2019.10.007","volume":"15","author":"S Mohan","year":"2020","unstructured":"Mohan S, Foy V, Ayub M, Leong HS, Schofield P, Sahoo S, et al. Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC. J Thorac Oncol. 2020;15:216\u201330.","journal-title":"J Thorac Oncol"},{"key":"3414_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05327-w","volume":"9","author":"J Nong","year":"2018","unstructured":"Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, et al. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018;9:3114.","journal-title":"Nat Commun"},{"key":"3414_CR23","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/1078-0432.CCR-19-0879","volume":"25","author":"S Devarakonda","year":"2019","unstructured":"Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, et al. Circulating tumor DNA profiling in small-cell lung cancer identifies potentially targetable alterations. Clin Cancer Res. 2019;25:6119\u201326.","journal-title":"Clin Cancer Res"},{"key":"3414_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20162-8","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yao Y, Xu Y, Li L, Gong Y, Zhang K, et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat Commun. 2021;12:11.","journal-title":"Nat Commun"},{"key":"3414_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","volume":"1","author":"CA Stewart","year":"2020","unstructured":"Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423\u201336.","journal-title":"Nat Cancer"},{"key":"3414_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60\u201378.e12.","journal-title":"Cancer Cell"},{"key":"3414_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","volume":"16","author":"MD Borromeo","year":"2016","unstructured":"Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16:1259\u201372.","journal-title":"Cell Rep"},{"key":"3414_CR28","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"3414_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466\u201370.","journal-title":"Nature"},{"key":"3414_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdq344","volume":"22","author":"DS Boss","year":"2011","unstructured":"Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an I.V. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22:431\u20137.","journal-title":"Ann Oncol"},{"key":"3414_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10637-014-0201-7","volume":"33","author":"C Dittrich","year":"2015","unstructured":"Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, et al. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest N Drugs. 2015;33:409\u201322.","journal-title":"Invest N Drugs"},{"key":"3414_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-016-3095-6","volume":"78","author":"K Mross","year":"2016","unstructured":"Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, et al. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharm. 2016;78:405\u201317.","journal-title":"Cancer Chemother Pharm"},{"key":"3414_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell. 2017;31:270\u201385.","journal-title":"Cancer Cell"},{"key":"3414_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1541-7786.MCR-13-0554","volume":"12","author":"M Cui","year":"2014","unstructured":"Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, et al. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res. 2014;12:654\u20139.","journal-title":"Mol Cancer Res"},{"key":"3414_CR35","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/1078-0432.CCR-25-2011","volume":"31","author":"C Ciardullo","year":"2025","unstructured":"Ciardullo C, Tobalina L, Carr TH, Szekeres P, Kraljevic S, Byers LA, et al. Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer. Clin Cancer Res. 2025;31:4457\u201362.","journal-title":"Clin Cancer Res"},{"key":"3414_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29517-9","volume":"13","author":"D Lissa","year":"2022","unstructured":"Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun. 2022;13:2023.","journal-title":"Nat Commun"},{"key":"3414_CR37","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1158\/1078-0432.CCR-23-0375","volume":"29","author":"K Ramkumar","year":"2023","unstructured":"Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, et al. Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clin Cancer Res. 2023;29:3237\u201349.","journal-title":"Clin Cancer Res"},{"key":"3414_CR38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","volume":"22","author":"CP Paweletz","year":"2016","unstructured":"Paweletz CP, Sacher AG, Raymond CK, Alden RS, O\u2019Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2016;22:915\u201322.","journal-title":"Clin Cancer Res"},{"key":"3414_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdy552","volume":"30","author":"C Abbosh","year":"2019","unstructured":"Abbosh C, Swanton C, Birkbak NJ. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann Oncol. 2019;30:358\u20139.","journal-title":"Ann Oncol"},{"key":"3414_CR40","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928\u201337.","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03414-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:07:16Z","timestamp":1779088036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03414-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,5]]}},"alternative-id":["3414"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03414-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L. Johnson reports research funding (paid to institution) from AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, Erasca, Genentech\/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, OncoMed Pharmaceuticals, Pfizer, PMV Pharmaceuticals, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals\/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL, and Y-mAbs Therapeutics, and consulting\/advisory roles (paid to institution) for AbbVie, Achilles Therapeutics, Amgen, AstraZeneca, Axelia Oncology, Atreca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech\/Roche, Genmab, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Ideaya Biosciences, iTeos, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Oncorus, Pfizer, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning Point Therapeutics, and WindMIL. G. Fabbri is an employee of, and reports ownership of stock\/shares in, AstraZeneca. C. Ciardullo is an employee of, and reports ownership of stock\/shares in, AstraZeneca. J.S. Wang reports honoraria from Regeneron, consulting fees from Fusion, and research funding (paid to institution) from AstraZeneca and several other pharmaceutical companies. G.S. Falchook reports advisory roles (paid to institution) for Fujifilm, Silicon, Navire, Turning Point, Predicine and (paid to self) EMD Serono, honoraria from Total Health Conferencing and Rocky Mountain Oncology Society, research funding (paid to institution) from 3-V Biosciences, Abbisko, AbbVie, ABL Bio ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO\/Eli Lilly, Artios, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Boehringer Ingelheim, Celldex, Celgene, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, IGM Biosciences, Ignyta, ImmunoGen\/MacroGenics, Incyte, Jacobio, Jounce, Kolltan, Loxo\/Bayer, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Navire, NiKang, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Pyramid, RasCal, Regeneron, Rgenix, Ribon, Samumed, Sapience, Silicon, Strategia, Syndax, Synthorx\/Sanofi, Taiho, Takeda, Tarveda, Teneobio, Tesaro, Tocagen, Turning Point Therapeutics, The University of Texas MD Anderson Cancer Center, Vegenics, and Xencor, royalties from Wolters Kluwer, and travel funding from Bristol Myers Squibb, EMD Serono, Fujifilm, Millennium, and Sarah Cannon Research Institute. S. Jones is an employee of HCA Healthcare and Sarah Cannon Research Institute, and reports ownership of stock\/shares in HCA. D. Strickland reports no conflicts. J. Sands reports honoraria from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Curadev, Daiichi-Sankyo, Fosun, Gilead, Guardant, Jazz Pharmaceutics, Medtronic, Merck, Novartis, Pfizer, Pharma Mar, Sanofi, and Takeda. C.M. Gay reports speaking engagement for AstraZeneca, BeiGene, MJH, OncLive, PeerView, and Targeted Healthcare; advisory board\/steering committee membership for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, G1 therapeutics Jazz Pharmaceuticals, and Monte Rosa Therapeutics; and consulting for Catalyst Pharmaceuticals, Kisoji Biotechnology, and STCube. R.J. Cardnell reports no conflicts of interest. L. Tobalina is an employee of, and reports ownership of stock\/shares in, AstraZeneca. S.E. Willis is an employee of, and reports ownership of stock\/shares in, AstraZeneca. J. Rodriguez-Canales was previously employed by AstraZeneca and is currently an employee of Daiichi Sankyo. M. Nikolaou is an employee of, and reports ownership of stock\/shares in, AstraZeneca. E.V. Jones is an employee of, and reports ownership of stock\/shares in, AstraZeneca. S. Schalkwijk was previously employed by AstraZeneca and is currently an employee of, and reports ownership of stock\/shares in, GlaxoSmithKline. L. Sainsbury is an employee of, and reports ownership of stock\/shares in, AstraZeneca. A. MacDonald is an employee of, and reports ownership of stock\/shares in, AstraZeneca. P. Overend is an employee of AstraZeneca and reports ownership of stock\/shares in AstraZeneca and GlaxoSmithKline. C. Kennedy is an employee of AstraZeneca, and reports ownership of stock\/shares in AstraZeneca, Amgen, and GlaxoSmithKline. J.E. Pease is an employee of, and reports ownership of stock\/shares in, AstraZeneca. P. Szekeres is an employee of AstraZeneca and reports ownership of stock\/shares in AstraZeneca and Eli Lilly. J. Cosaert is an employee of, and reports ownership of stock\/shares in, AstraZeneca. H. Burris III is an employee of, and reports ownership of stock\/shares in, HCA Healthcare and Sarah Cannon Research Institute, and reports non-compensated consulting for Daiichi Sankyo, Pfizer, Bayer, GRAIL, Novartis, Vincerx Pharma, AstraZeneca and Incyte, and research grants or funds (paid to institution) from Roche\/Genentech, BMS, Incyte, AstraZeneca, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Merck, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX, GlaxoSmithKline, Verastem, Tesaro, BioMed Valley Discoveries, TG Therapeutics, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, BioAtla, CicloMed, Harpoon Therapeutics, Arch, Arvinas, Revolution Medicine, Array BioPharma, Bayer, BIND Therapeutics, Kymab, miRNA Therapeutics, Pfizer, Takeda\/Millennium, Foundation Medicine, EMD Serono, ARMO BioSciences, CALGB, Hengrui Therapeutics, Infinity Pharmaceuticals, XBiotech, Zymeworks, Coordination Pharmaceuticals, NGM Biopharmaceuticals, Gossamer Bio, Ryvu Therapeutics, BioTheryX, and AbbVie. L.A. Byers is an employee of The University of Texas MD Anderson Cancer Center, and reports consulting fees from Boehringer Ingelheim, Chugai Pharmaceuticals, AstraZeneca, Genentech, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen, Daiichi Sankyo, and Novartis; honoraria from Clinical Care Options and UpToDate; patents royalties and other intellectual property for molecular subtyping of small cell lung cancer to predict therapeutic responses (U.S. Patent No: 11,732,306); methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas;\u00a0and grants or funds from AstraZeneca, Amgen, and Bristol Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Conference on Harmonisation (ICH)\/Good Clinical Practice (GCP) guidelines, applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples. The study protocol and all modifications were approved by relevant ethics committees or institutional review boards: IntegReview, Austin, TX; MD Anderson IRB, Houston, TX; Dana Farber Cancer Institute IRB, Boston, MA; WIRB, Puyallup, WA. It was a requirement for each patient to provide signed and dated informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}